A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis

To investigate in a pilot study the safety and efficacy of infliximab in patients with refractory dermatomyositis (DM) and polymyositis (PM).

Source: Seminars in Arthritis and Rheumatism - October 14, 2017 Category: Rheumatology Authors: Adam Schiffenbauer, Megha Garg, Christine Castro, Angelina Pokrovnichka, Galen Joe, Joseph Shrader, Imelda Victoria Cabalar, Sara Faghihi-Kashani, Michael O. Harris-Love, Paul H. Plotz, Frederick W. Miller, Mark Gourley Source Type: research